Suppr超能文献

[中国心脏瓣膜手术低抗凝治疗登记与随访多中心研究]

[The multicenter study on the registration and follow-up of low anticoagulation therapy for the heart valve operation in China].

作者信息

Dong L, Shi Y K, Xu J P, Zhang E Y, Liu J C, Li Y X, Ni Y M, Yang Q, Han T, Fu B, Chen J, Ren L, Wei S L, Chen H, Liu K X, Yu F X, Liu J S, Xiao M D, Wu S M, Zhang K L, Huang H L, Jiang S L, Qiao C H, Wang C S, Xu Z Y, Zhou X M, Wang D J, Ni L X, Xiao Y B, Jiang S L, Zhang G M, Liang G Y, Yang S Y, Bo P, Zhong Q J, Zhang J B, Zhang X, Zhu Y B, Teng X, Zhu P, Huang F, Xiao Y M, Cao G Q, Tian H, Xia L M, Lu F L, Liu Y Q, Liu D X, Xu H, Yuan Y, Li M, Chang C, Wu X C, Xu Z, Guo P, Bai Y J, Xue W B, Jiang X Y, Na Z H, Zeng Q Y, Cai H, Wang Y L, Xiong R, Jin S, Zheng X M, Wu D

机构信息

Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2016 May 24;96(19):1489-94. doi: 10.3760/cma.j.issn.0376-2491.2016.19.006.

Abstract

OBJECTIVE

To investigate the optimal anticoagulation methods and monitoring strategy for Chinese patients undergoing heart valve replacement, which is potentially quite different from western populations.

METHODS

In this multicenter prospective cohort study, the anticoagulation and monitoring strategy data was acquired from 25 773 in-hospital patients in 35 medical centers and 20 519 patients in outpatient clinic in 11 medical centers from January 1st, 2011 to December 31th, 2015.

RESULTS

As for in-hospital patients, mean age of study population was (48.6±11.2) years old; main etiology of valve pathology was rheumatic (87.5%) origin among study cohort; 94.8% of study population received mechanical valve implantation; international normalized ratio (INR) monitoring (in all the study centers) and low-intensity anticoagulation strategy (31 hospitals chose target INR range of 1.5-2.5, and actual values of INR among 89.2% of 100 069 in-hospital monitoring samples were 1.5-2.5), with mean actual INR values of 1.84±0.53, and warfarin dosage of (2.82±0.93) mg/d were widely adopted among the study centers; strategies of in-hospital warfarin administration were similar in all the study centers; complication rates of low-intensity anticoagulation strategy were low in severe hemorrhage (0.02%), thrombosis (0.05%), and thromboembolism (0.05%) events, without anticoagulation-related death.As for 18 974 outpatient clinic patients, the follow-up rate was 92.47%, with a total of 30 012 patient-years (Pty). Anticoagulation-related morbidity and mortality rates were 0.67% and 0.15% Pty; major hemorrhage morbidity and mortality rates were 0.25% and 0.13% Pty; thromboembolism morbidity and mortality rates were 0.45% and 0.03% Pty.The mean dosage of warfarin daily dosage was (2.85±1.23) mg/d and INR value was 1.82±0.57.No significant regional difference in the intensity of anticoagulation therapy was noted during the study.

CONCLUSIONS

INR can be used as a normalized indicator for intensity of anticoagulation therapy in China.The optimal anticoagulation intensity with INR range from 1.5 to 2.5 is safe and effective for Chinese patients with heart valve replacement, and there is no significant regional difference in the intensity of anticoagulation therapy.

摘要

目的

探讨与西方人群可能存在显著差异的中国心脏瓣膜置换患者的最佳抗凝方法及监测策略。

方法

在这项多中心前瞻性队列研究中,收集了2011年1月1日至2015年12月31日期间35个医疗中心25773例住院患者以及11个医疗中心20519例门诊患者的抗凝及监测策略数据。

结果

住院患者中,研究人群的平均年龄为(48.6±11.2)岁;瓣膜病变的主要病因是风湿性(87.5%);94.8%的研究人群接受了机械瓣膜植入;国际标准化比值(INR)监测(在所有研究中心)以及低强度抗凝策略(31家医院选择目标INR范围为1.5 - 2.5,在100069例住院监测样本中,89.2%的INR实际值为1.5 - 2.5)被各研究中心广泛采用,平均实际INR值为1.84±0.53,华法林剂量为(2.82±0.93)mg/d;各研究中心住院期间华法林给药策略相似;低强度抗凝策略在严重出血(0.02%)、血栓形成(0.05%)和血栓栓塞(0.05%)事件中的并发症发生率较低,无抗凝相关死亡。对于18974例门诊患者,随访率为92.47%,总计30012患者年(Pty)。抗凝相关发病率和死亡率分别为0.67%和0.15%Pty;大出血发病率和死亡率分别为0.25%和0.13%Pty;血栓栓塞发病率和死亡率分别为0.45%和0.03%Pty。华法林每日平均剂量为(2.85±1.23)mg/d,INR值为1.82±0.57。研究期间未观察到抗凝治疗强度存在显著地区差异。

结论

INR可作为中国抗凝治疗强度的标准化指标。INR范围为1.5至2.5的最佳抗凝强度对中国心脏瓣膜置换患者安全有效,且抗凝治疗强度无显著地区差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验